GlaxoSmithKline, Catamaran, GE, HealthPrize and Proteus join RE’s “Disrupting Drug/Dx Reimbursement”

Real Endpoints and Ernst & Young add new panels/discussions to the already robust agenda for the Real Endpoints Symposium “The Future is Now: Disrupting Drug/Dx Reimbursement” this March in Philadelphia.

Online PR News – 06-February-2013 – Westport, CT – Thomas Kottler, Chief Executive Officer, HealthPrize Technologies LLC, David O’Reilly, Chief Product Officer, Proteus Digital Health, and Risa Stack, General Manager, Emerging Health Innovations, Ge healthymagination to headline the panel “Start-ups: Innovation at the Product-Payer Intersection”. Innovation in the context of drugs has always meant new therapeutics. But this panel of start-ups and new-style investors shows that innovation thrives in the crucial area of making pharmacology work better — and more cost-effectively.

As the fourth largest US pharmacy benefits manager, Catamaran aims to out-sail its larger competitors by investing in innovations that both promote its high-touch service model and aggressively manage pharmacy costs, especially those associated with high-priced specialty drugs. But can the company continue to keep the wind at its back while making big money investments aimed at reducing drug spend? In this key note, “Managing Total Healthcare Costs: Where Innovation and Prescription Benefit Management Intersect,” Catamaran’s clinical innovation chief, Carl Bertram, explains why the terms “PBM” and “Innovation” belong in the same sentence.

Lynn Marks, MD, SVP, Projects, Clinical Platforms & Sciences Pharmaceuticals R&D, GlaxoSmithKline, will join Lewis Sandy, MD, FACP, SVP, Clinical Advancement, UnitedHealth Group and Principal, UnitedHealth Center for Reform and Modernization, and Robert Galvin, MD, CEO, Equity Health in a Fireside Chat: “Finding Common Ground,” moderated by Roger Longman, CEO, Real Endpoints. Payers and employers often see corporate R&D as largely a mechanism to increase prices. Pharmas just as often see payers and corporate healthhcare buyers as the enemies of medical progress. Leading medical trendsetters on each side of the debate sit down for a no-holds-barred discussion on the role of innovation in medicine today — and in particular whether, and how, pharma and diagnostic companies can deliver what buyers really need.

About Real Endpoints Symposium
Real Endpoints Symposium brings together senior executives from leading life sciences companies, payers, providers, and policy makers to discuss new solutions and innovative strategies to address the rapidly changing reimbursement environment in healthcare. This unique forum, entitled “The Future is Now: Disrupting Drug/Dx Reimbursement,” will be co-hosted by Ernst & Young and Real Endpoints, and will take place March 11-12, 2013 at the Hyatt Regency in Philadelphia,

About Real Endpoints
RE operates at the critical intersection between payers, at-risk providers, and medical product developers, assisting each to successfully navigate an increasingly complex marketplace. We do this by developing and delivering the must-have information and services these stakeholders need to compete successfully. Our goal: support the process of innovation by helping our customers improve the quality and cost of the services and products they provide, realize greater value, and deliver improved health outcomes.